ClinicalTrials.gg
RecruitingNCT07695376CARAMEL-OSUpdated Jul 10, 2026

CARAMEL Observational Study

An observational study in Perimenopause, Menopause and Cardiovascular (CV) Risk, sponsored by Biogipuzkoa Health Research Institute. Recruiting at 6 sites in 5 countries. Open to female participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Biogipuzkoa Health Research Institute · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
40 Years to 60 Years
Sex
Female
01

Study summary

CARAMEL is a project funded by the European Commission under the Horizon Europe programme. Its aim is to develop a personalized prevention approach based on state-of-the-art artificial intelligence models for cardiovascular risk stratification in women aged 40-60 years. These models are trained using large amounts of multi-source data and complemented by digital self-assessment and self-management tools. The CARAMEL consortium brings together a diverse group of 25 organizations, including technology companies and research centers, clinical institutions, as well as experts in ethics, law, and communication.

The CARAMEL-OS study is an observational study aimed at prospectively completing the proposed personalized cardiovascular risk stratification model for women aged 40-60 years that will be developed during the earlier phases of the overall CARAMEL project (https://www.caramel-project.eu/).

The study has a purely observational design, and patient stratification will not entail any clinical intervention. The data collected will be used to complete the design of the personalized stratification model, as well as to develop and validate the performance of the predictive models in an independent prospective cohort, distinct from the retrospective cohort initially used. The performance of the models developed using retrospective data will be assessed in terms of accuracy, discrimination, calibration, and other relevant metrics. In addition, the study will enable the development of new predictive models with short-term prediction horizons, incorporating additional variables that are not available retrospectively.

The study population will be recruited in four European Union countries: Croatia, Spain (Andalusia and The Basque Country - Gipuzkoa), Greece and Lithuania; and in Colombia. A prospective cohort of 3,000 women aged 40-60 will be recruited, with each partner contributing 500 participants.

Read the detailed description

A prospective observational study involving 3,000 women across six clinical sites will be conducted to generate a comprehensive multi-source dataset for the development of cardiovascular disease (CVD) risk assessment models. In addition to socioeconomic, clinical, biochemical, and imaging data, the study will use novel non-invasive technologies to collect additional potentially relevant variables, aiming to improve understanding of female-specific cardiovascular risk factors and biological changes around menopause age. By refining the CARAMEL stratification scheme based on the most effective approaches, the project aims to provide innovative tools for personalized CVD prevention and risk stratification. This ambitious and integrative approach is expected to advance precision medicine in women's cardiovascular health, support clinical decision-making, and inform future preventive strategies at both individual and population levels. Central to these strategies is the development of the datApp - a mobile application designed to serve as a personalised companion for women throughout their menopausal transition.

02

Conditions studied

  • Perimenopause
  • Menopause
  • Cardiovascular (CV) Risk
  • Women (Between 30 to 60 Years Old)
  • Cardiovascular Disease Risk Factor
  • Artificial Intelligence (Al)

Keywords

  • Women-specific risk factors
  • Cardiovascular (CV) Risk
  • Perimenopause
  • Menopause
  • Prediction models
  • Patient reported outcomes (PROM)
03

In context

Lead sponsor

Biogipuzkoa Health Research Institute is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be recruited in four European Union countries: Croatia, Spain (Andalusia and The Basque Country - Gipuzkoa), Greece and Lithuania; and in Colombia. A prospective cohort of 3,000 women aged 40-60 will be recruited, with each partner contributing 500 participants.

Eligible women may be invited to participate by their regular healthcare provider or may express their interest independently. To maximize representativeness, information about the study will be disseminated via multiple communication channels, including social media platforms (e.g., LinkedIn, Facebook, Bluesky, X). Women who express interest will be contacted by the CARAMEL research team, and detailed study documentation will be provided.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women 40 to 60 years of age, at recruitment.
  • Ability to understand and complete the required for the study.
  • Women who are covered by the corresponding healthcare system operating at each clinical site.

Exclusion criteria

Exclusion Criteria:

  • Severe comorbidity with less than 24 months .
  • Lack of basic digital skills to use or carry a smartphone and wearable devices.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • 3,000 women aged 40-60 recruited in four European Union countries and Colombia.

    The study population will be recruited in five sites belonging to four European Union countries: Croatia, Spain (Andalusia and The Basque Country - Gipuzkoa), Greece and Lithuania; and one South America country that is Colombia. A prospective cohort of 3,000 women aged 40-60 will be recruited, with each partner contributing 500 participants.

06

What researchers measure

Primary outcomes

  1. Incidence of hypertension

    Incidence of hypertension will be assessed by measuring blood pressure during the baseline and final study visits, as well as by reviewing the diagnosis of hypertension recorded in the electronic health records. Participants enrolled during a self-monitoring month will be asked to measure their blood pressure twice daily throughout 1 month.

    Time frame: From enrollment to program completion, spanning 21-24 months depending on the enrollment date.

  2. Incidence of dyslipidaemia

    Incidence of dyslipidaemia will be assessed through blood tests measuring HDL cholesterol, LDL cholesterol, total cholesterol, and triglyceride levels at the baseline and final study visits, as well as by reviewing diagnoses of dyslipidaemia recorded in the electronic health records.

    Time frame: From enrollment to program completion, lasting 21-24 months depending on the enrollment date.

  3. Incidence of diabetes mellitus

    Incidence of diabetes mellitus will be assessed through blood tests measuring glomerular filtration rate, albumin-to-creatinine ratio, glucose and glycated hemoglobin levels at the baseline and final study visits, as well as by reviewing diagnoses of diabetes mellitus recorded in the electronic health records.

    Time frame: From enrollment to program completion, lasting 21-24 months depending on the enrollment date.

  4. Incidence of cardiovascular disease

    The incidence of cardiovascular disease will be assessed through the diagnosis of the following conditions: myocardial infarction, chronic coronary syndrome, peripheral arterial disease, and stroke. This information will be collected through a structured medical history interview and by reviewing the electronic health records. These data will be collected during the baseline visit and the final visit.

    Time frame: From enrollment to program completion, spanning 21-24 months depending on the enrollment date.

Secondary outcomes

  1. Mortality of cardiovascular events.

    Mortality of cardiovascular events will be assessed through review of electronic health records, collecting information on new cardiovascular events and mortality occurring during the follow-up period and identified at the final assessment.

    Time frame: From enrollment to program completion, spanning 21-24 months depending on the enrollment date.

07

Study locations

3 of 6 sites recruiting
  • Keralty SAS
    Bogotá, Colombia
    Not yet recruiting
  • Magdalena - Klinika Za Kardiovaskularne Bolesti Medicinskog Fakultetasveucilista J.J. Strossmayera U Osijeku Ustanova
    Krapinske Toplice, Croatia
    Not yet recruiting
  • Ethniko Kai Kapodistriako Panepistimio Athinon
    Athens, Greece
    Recruiting
  • Viesoji Istaiga Vilniaus Universiteto Ligonine Santaros Klinikos
    Vilnius, Lithuania
    Not yet recruiting
  • Biogipuzkoa Health Research Institute
    San Sebastián, Spain
    Recruiting
  • Fundacion Para La Gestion de La Investigacion En Salud de Sevilla
    Seville, Spain
    Recruiting
08

References and documents

Publications

  • Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, Bura-Riviere A, De Backer J, Deglise S, Della Corte A, Heiss C, Kaluzna-Oleksy M, Kurpas D, McEniery CM, Mirault T, Pasquet AA, Pitcher A, Schaubroeck HAI, Schlager O, Sirnes PA, Sprynger MG, Stabile E, Steinbach F, Thielmann M, van Kimmenade RRJ, Venermo M, Rodriguez-Palomares JF; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024 Sep 29;45(36):3538-3700. doi: 10.1093/eurheartj/ehae179. No abstract available. PubMed 39210722 ↗
  • Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177. No abstract available. PubMed 39210710 ↗
  • Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264. doi: 10.1016/j.jacc.2018.08.1038. Epub 2018 Aug 25. No abstract available. PubMed 30153967 ↗
  • American Diabetes Association Professional Practice Committee. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 Suppl 1):S14-S26. doi: 10.2337/dc25-S001. PubMed 39651974 ↗
  • Cherla A, Kyriopoulos I, Pearcy P, Tsangalidou Z, Hajrulahovic H, Theodorakis P, Andersson CE, Mehra MR, Mossialos E. Trends in avoidable mortality from cardiovascular diseases in the European Union, 1995-2020: a retrospective secondary data analysis. Lancet Reg Health Eur. 2024 Sep 27;47:101079. doi: 10.1016/j.lanepe.2024.101079. eCollection 2024 Dec. PubMed 39397877 ↗
  • McCarthy CP, Bruno RM, McEvoy JW, Touyz RM. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy? Eur Heart J Cardiovasc Pharmacother. 2025 Feb 8;11(1):7-9. doi: 10.1093/ehjcvp/pvae084. No abstract available. PubMed 39439212 ↗
  • Rajput D, Wang WJ, Chen CC. Evaluation of a decided sample size in machine learning applications. BMC Bioinformatics. 2023 Feb 14;24(1):48. doi: 10.1186/s12859-023-05156-9. PubMed 36788550 ↗
  • Kouz K, Monge Garcia MI, Cerutti E, Lisanti I, Draisci G, Frassanito L, Sander M, Ali Akbari A, Frey UH, Grundmann CD, Davies SJ, Donati A, Ripolles-Melchor J, Garcia-Lopez D, Vojnar B, Gayat E, Noll E, Bramlage P, Saugel B. Intraoperative hypotension when using hypotension prediction index software during major noncardiac surgery: a European multicentre prospective observational registry (EU HYPROTECT). BJA Open. 2023 May 4;6:100140. doi: 10.1016/j.bjao.2023.100140. eCollection 2023 Jun. PubMed 37588176 ↗
  • Lopez-Lopez JP, Garcia-Pena AA, Martinez-Bello D, Gonzalez AM, Perez-Mayorga M, Munoz Velandia OM, Ruiz-Uribe G, Campo A, Rangarajan S, Yusuf S, Lopez-Jaramillo P. External validation and comparison of six cardiovascular risk prediction models in the Prospective Urban Rural Epidemiology (PURE)-Colombia study. Eur J Prev Cardiol. 2025 May 12;32(7):564-572. doi: 10.1093/eurjpc/zwae242. PubMed 39041366 ↗
  • SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023 Jul 21;44(28):2544-2556. doi: 10.1093/eurheartj/ehad260. PubMed 37247330 ↗
  • Goldenholz DM, Sun H, Ganglberger W, Westover MB. Sample Size Analysis for Machine Learning Clinical Validation Studies. Biomedicines. 2023 Feb 23;11(3):685. doi: 10.3390/biomedicines11030685. PubMed 36979665 ↗
  • Powell-Wiley TM, Baumer Y, Baah FO, Baez AS, Farmer N, Mahlobo CT, Pita MA, Potharaju KA, Tamura K, Wallen GR. Social Determinants of Cardiovascular Disease. Circ Res. 2022 Mar 4;130(5):782-799. doi: 10.1161/CIRCRESAHA.121.319811. Epub 2022 Mar 3. PubMed 35239404 ↗
  • NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 Sep 11;398(10304):957-980. doi: 10.1016/S0140-6736(21)01330-1. Epub 2021 Aug 24. PubMed 34450083 ↗
  • SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul 1;42(25):2439-2454. doi: 10.1093/eurheartj/ehab309. PubMed 34120177 ↗
  • Liu W, Laranjo L, Klimis H, Chiang J, Yue J, Marschner S, Quiroz JC, Jorm L, Chow CK. Machine-learning versus traditional approaches for atherosclerotic cardiovascular risk prognostication in primary prevention cohorts: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2023 Jun 21;9(4):310-322. doi: 10.1093/ehjqcco/qcad017. PubMed 36869800 ↗
  • Ballena-Caicedo J, Zuzunaga-Montoya FE, Loayza-Castro JA, Vasquez-Romero LEM, Tapia-Limonchi R, De Carrillo CIG, Vera-Ponce VJ. Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis. J Health Popul Nutr. 2025 Aug 26;44(1):308. doi: 10.1186/s41043-025-01054-3. PubMed 40859400 ↗
  • Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983 Sep;148(3):839-43. doi: 10.1148/radiology.148.3.6878708. PubMed 6878708 ↗
  • Diabetes Atlas. Country [Internet]. 2025 [cited 2025 Nov 1]. Available from: https://diabetesatlas.org/data-by-location/country/
  • Evolución de la prevalencia de la diabetes mellitus en España (1999-2014) - ClinicalKey [Internet]. 2018 [cited 2025 Nov 1]. Available from: https://www.clinicalkey.es/#!/content/playContent/1-s2.0-S253001641830171X?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS253001641830171X%3Fshowall%3Dtrue&referrer=
  • Banegas JR, Sanchez-Martinez M, Gijon-Conde T, Lopez-Garcia E, Graciani A, Guallar-Castillon P, Garcia-Puig J, Rodriguez-Artalejo F. Numerical values and impact of hypertension in Spain. Rev Esp Cardiol (Engl Ed). 2024 Sep;77(9):767-778. doi: 10.1016/j.rec.2024.03.011. Epub 2024 May 1. English, Spanish. PubMed 38701882 ↗
  • Samplingbook package - RDocumentation [Internet]. 2025 [cited 2025 Nov 1]. Available from: https://www.rdocumentation.org/packages/samplingbook/versions/1.2.4
  • Front matter. In: Sample size tables for clinical studies [Internet]. Chichester: John Wiley & Sons, Ltd; 2008 [cited 2025 Nov 1]. p. i-viii. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/9781444300710.fmatter
  • James G, Witten D, Hastie T, Tibshirani R. An introduction to statistical learning: with applications in R [Internet]. New York (NY): Springer US; 2021 [cited 2025 Nov 1]. (Springer Texts in Statistics). Available from: https://link.springer.com/10.1007/978-1-0716-1418-1
  • Gholamy A, Kreinovich V, Kosheleva O. Why 70/30 or 80/20 relation between training and testing sets: a pedagogical explanation [Internet]. Departmental Technical Reports (CS); 2018 [cited 2025 Nov 1]. Available from: https://www.scirp.org/reference/referencespapers?referenceid=3324183
  • Hotter GJ. [Severe forms of tuberculosis observed during the past year (author's transl)]. Prax Klin Pneumol. 1979 Apr;33 Suppl 1:582-6. German. PubMed 461350 ↗
  • Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. No abstract available. PubMed 31504418 ↗
  • Homepage | Globorisk [Internet]. [cited September 14, 2025]. Available at: https://www.globorisk.org/
  • WHO updates Cardiovascular Risk Charts [Internet]. [cited September 14, 2025]. Available at: https://www.who.int/news/item/02-09-2019-who-updates-cardiovascular-risk-charts
  • DANE - Vital statistics: births and deaths [Internet]. [cited September 14, 2025]. Available at: https://www.dane.gov.co/index.php/estadisticas-por-tema?id=34&phpMyAdmin=3om27vamm65hhkhrtgc8rrn2g4
  • Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G, Pozo-Rosich P, Dorman PJ, Nezadal T, Poole AC, Martins IP, Sumelahti ML, Ramirez Campos V, Ahn AH, Lyras L, Tassorelli C. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. Cephalalgia. 2023 Nov;43(11):3331024231214987. doi: 10.1177/03331024231214987. PubMed 37987641 ↗
  • Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, Mereckiene J, Knol M, Winje BA, Ciruela P, de Miguel S, Guevara M, MacDonald L, Kozakova J, Slotved HC, Fry NK, Pekka Nuorti J, Danis K, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Sanz JC, Castilla J, Smith A, Colzani E, Pastore Celentano L, Hanquet G; SpIDnet VE study group. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022 Jun 23;40(29):3963-3974. doi: 10.1016/j.vaccine.2022.05.011. Epub 2022 May 28. PubMed 35637067 ↗
  • Balki I, Amirabadi A, Levman J, Martel AL, Emersic Z, Meden B, Garcia-Pedrero A, Ramirez SC, Kong D, Moody AR, Tyrrell PN. Sample-Size Determination Methodologies for Machine Learning in Medical Imaging Research: A Systematic Review. Can Assoc Radiol J. 2019 Nov;70(4):344-353. doi: 10.1016/j.carj.2019.06.002. Epub 2019 Sep 12. PubMed 31522841 ↗
  • Bell KJL, White S, Hassan O, Zhu L, Scott AM, Clark J, Glasziou P. Evaluation of the Incremental Value of a Coronary Artery Calcium Score Beyond Traditional Cardiovascular Risk Assessment: A Systematic Review and Meta-analysis. JAMA Intern Med. 2022 Jun 1;182(6):634-642. doi: 10.1001/jamainternmed.2022.1262. PubMed 35467692 ↗
  • Refaee MA, Al-Absi HRH, Islam MT, Househ M, Shah Z, Rahman MS, Alam T. The Linkage Between Bone Densitometry and Cardiovascular Disease. Stud Health Technol Inform. 2022 Jan 14;289:244-247. doi: 10.3233/SHTI210905. PubMed 35062138 ↗
  • Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1175-80. doi: 10.1161/01.atv.0000022015.97341.3a. PubMed 12117734 ↗
  • Georgiopoulos G, Mavraganis G, Delialis D, Georgiou S, Aivalioti E, Patras R, Petropoulos I, Dimopoulou MA, Angelidakis L, Sianis A, Bampatsias D, Dimoula A, Maneta E, Kosmopoulos M, Vardavas C, Stellos K, Stamatelopoulos K. Carotid ultrasonography improves residual risk stratification in guidelines-defined high cardiovascular risk patients. Eur J Prev Cardiol. 2022 Oct 18;29(13):1773-1784. doi: 10.1093/eurjpc/zwac095. PubMed 35580589 ↗
  • Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engstrom G, Evans GW, de Graaf J, Grobbee DE, Hedblad B, Hofman A, Holewijn S, Ikeda A, Kavousi M, Kitagawa K, Kitamura A, Koffijberg H, Lonn EM, Lorenz MW, Mathiesen EB, Nijpels G, Okazaki S, O'Leary DH, Polak JF, Price JF, Robertson C, Rembold CM, Rosvall M, Rundek T, Salonen JT, Sitzer M, Stehouwer CD, Witteman JC, Moons KG, Bots ML. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012 Aug 22;308(8):796-803. doi: 10.1001/jama.2012.9630. PubMed 22910757 ↗
  • Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, Guerrero M, Kunadian V, Lam CSP, Maas AHEM, Mihailidou AS, Olszanecka A, Poole JE, Saldarriaga C, Saw J, Zuhlke L, Mehran R. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021 Jun 19;397(10292):2385-2438. doi: 10.1016/S0140-6736(21)00684-X. Epub 2021 May 16. PubMed 34010613 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartActual
Mar 16, 2026
Primary completionEst.
May 2028
CompletionEst.
Nov 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07695376
Lead sponsor
Biogipuzkoa Health Research Institute
Collaborators
Fundación Centro de Tecnologías de Interacción Visual y Comunicaciones Vicomtech, Keralty SAS, Particle Summary, iBreve Limited, Magdalena Clinic, Andaluz Health Service, Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Viesoji Istaiga Vilniaus Universiteto Ligonine Santaros Klinikos, Asociación Centro de Investigación Cooperativa en Biociencias, Ulma Medical Technologies S Coop, Smartnanosenose Innovation, ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Mar 16, 2026
Primary completion
May 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Primary Care - OSIs Research Unit
Contact
unidadinvestigaciongip@osakidetza.eus
(+34)943006086

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion